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Abstract: To examine the correlation between the struc-
ture of Bcl-2 and its inhibitory function of c-Jun N-termi-
nal kinase (JNK) and caspase activity, we established a
dopaminergic neuronal cell line, MN9D overexpressing
Bcl-2 (MN9D/Bcl-2) or its structural mutants. The mu-
tants comprised a point mutation in the BH1 (G145A;
MN9D/BH1) or BH2 (W188A; MN9D/BH2) domain and a
deletion mutation in the C-terminal (MN9D/C22), BH3
(MN9D/BH3), or BH4 (MN9D/BH4) domain. As deter-
mined by the TUNEL (terminal deoxynucleotidyltrans-
ferase nick end-labeling) and MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction
assay, apoptotic death of MN9D/Neo cells reached 80–
90% within 24 h in response to 1 mM staurosporine.
Upon staurosporine treatment, JNK activity increased
six- to sevenfold over the basal level within 2–4 h. Treat-
ment of MN9D/Neo with both staurosporine and a
caspase inhibitor, Z-VAD, attenuated cell death without
suppressing JNK activation. Both staurosporine-induced
cell death and JNK activation were attenuated in MN9D/
Bcl-2. As determined by cleavage of poly(ADP-ribose)
polymerase into 85 kDa, Bcl-2 blocked caspase activity
as well. When cells overexpressing one of the Bcl-2 mu-
tants were treated with staurosporine, death was atten-
uated in MN9D/BH1, MN9D/BH2, and MN9D/C22 but not
in MN9D/BH3 and MN9D/BH4. Similarly, both JNK and
caspase activation were blocked in MN9D/BH1, MN9D/
BH2, and MN9D/C22, whereas they were not suppressed
in MN9D/BH3 and MN9D/BH4. Taken together, our data
indicate that there exists a close structural and functional
correlation of Bcl-2 to JNK and caspase activity in stau-
rosporine-induced dopaminergic neuronal cell death.
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Apoptosis, also known as programmed cell death, is a
highly regulated process by which an organism activates
an intracellular death program and eliminates unneces-
sary, aged, or damaged cells (Wyllie, 1993). Apoptotic
cells shrink and are rapidly taken up by neighboring cells
before they elicit an inflammatory response. Given an
abnormal internal and/or external proapoptotic signal(s),
cells can undergo aberrant control of the positive and
negative regulators of cell death, resulting in various
pathological conditions including neurodegenerative dis-
orders (Thompson, 1995).
Among many proposed mechanisms, activation of
CED-3/ICE (interleukin-1-b-converting enzyme)-like pro-
teases, recently termed caspases, seems to be a key element
in the effector phase of apoptotic cell death in many
paradigms (Alnemri et al., 1996; Cryns and Yuan, 1998).
Once activated by a proteolytic cascade in response to
proapoptotic signals, caspases kill cells by cleaving the
specific cellular target proteins, using a variety of strat-
egies (Kaufmann et al., 1993; Lazebnik et al., 1994;
Cryns and Yuan, 1998). One of several mammalian
mitogen-activated protein kinases, c-Jun N-terminal ki-
nase (JNK), has been also demonstrated to mediate an
early intracellular signaling pathway, eventually leading
to apoptosis upon exposure to a variety of stresses (Ham
et al., 1995; Xia et al., 1995; Verheij et al., 1996).
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Although the signaling apparatus involved in activation
of the caspase remains to be further delineated, JNK
signaling has been linked to both caspase-dependent and
-independent cell death pathways (Muhlenbeck et al.,
1998; Zanke et al., 1998).
Numerous studies have demonstrated that the 26-kDa
membrane-associated protein Bcl-2 is a prototypic neg-
ative regulator of apoptosis and necrosis in some cases as
demonstrated both in vivo and in vitro (Reed, 1994;
Kane et al., 1995; Choi et al., 1999). Until now, 15
death-inducing and death-inhibitory members of the
Bcl-2 family have been identified in mammalian cells
(Adams and Cory, 1998). All members possess at least
one of four conserved motifs known as Bcl-2 homology
domains (BH1 to BH4). Most members of the Bcl-2
family possess a carboxy-terminal membrane anchorage
domain (Kroemer, 1997). Although these domains seem
to be involved in determining the fate of cells upon
stresses, it remains to be elucidated how these domains
participate in regulating the cell death process and whether
there exists cell-type and/or stress-type specificity.
Recently, we have demonstrated that (1) Bcl-2 blocks
staurosporine-induced neuronal apoptotic cell death (Oh
et al., 1997) and (2) Bcl-2 disrupts a signaling cascade
leading to JNK activation induced by various apoptotic
stresses including staurosporine (Park et al., 1997). In the
present study, we have used a dopaminergic neuronal
cell line, MN9D overexpressing Bcl-2 and its structural
mutants, to investigate a close correlation between the
structure of Bcl-2 and its function to inhibit JNK and
caspase activity in staurosporine-induced neuronal cell
death.
MATERIALS AND METHODS
Establishment of stable cell lines
MN9D cells were cultured in 90% Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated fetal
bovine serum (Gibco) in an atmosphere of 10% CO2. For
establishing stable cell lines, MN9D cells plated at ;2 3 106
cells onto a 25 mg/ml poly-D-lysine-coated six-well plate
(Corning) were transfected with a cytomegalovirus promoter/
enhancer-driven eukaryotic expression vector, pCMV/Neo,
containing a full-length human Bcl-2 cDNA (MN9D/Bcl-2) or
one of the several Bcl-2 mutant cDNAs using Lipofectamine
(Gibco), as previously described (Oh et al., 1998). Structural
mutants included Bcl-2/BH1 (G145A; MN9D/BH1), Bcl-2/
BH2 (W188A; MN9D/BH2), Bcl-2/C22 (carboxy-terminal 22-
amino acid deletion mutant; MN9D/C22), Bcl-2/BH3 (BH3
domain deletion mutant; MN9D/BH3), and Bcl-2/BH4 (BH4
domain deletion mutant; MN9D/BH4). MN9D cells transfected
with a vector without these sequences were used as control
(MN9D/Neo). These transfectants were selected in a medium
containing 90% Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum and 500 mg/ml G-418
(complete culture medium; CCM) for 7–10 days. Colonized
clones were picked, expanded in CCM, and characterized by
immunoblot analysis as described below.
Immunoblot analysis and immunocytochemistry
For measuring the expression levels of Bcl-2 and its struc-
tural mutant proteins, cells (.5 3 106) cultured on poly-D-
lysine-coated P-100 dishes (Corning) were washed with ice-
cold phosphate-buffered saline (PBS) and lysed in a buffer
containing 50 mM Tris (pH 7.0)/2 mM EDTA/1% Triton
X-100/2 mM phenylmethylsulfonyl fluoride/50 mg/ml aprotinin
for 15 min. Lysates were microcentrifuged at 13,000 g for 30
min at 4°C. After measurement of the protein content of the
resulting supernatants using a Bio-Rad protein assay kit, 50 mg
of protein from each sample was separated on a 12.5% sodium
dodecyl sulfate (SDS)–polyacrylamide gel, blotted onto prewet
polyvinylidene difluoride–nitrocellulose filters, processed for
immunoblot analysis, and then developed using an enhanced
chemiluminescence kit (Amersham). Rabbit polyclonal anti-
Bcl-2 was used as primary antibody (1:3,000; Krajewski et al.,
1993). For detecting the cleavage pattern of poly(ADP-ribose)
polymerase (PARP) following staurosporine treatment, mouse
monoclonal anti-PARP was used as primary antibody (1;5,000;
Enzyme Systems Products; Kim et al., 1999). For immunocy-
tochemistry, cells were fixed in 4% paraformaldehyde and
permeabilized in PBS containing 0.1% Triton X-100 and 1%
bovine serum albumin. Subsequently, cells were incubated with
a hamster monoclonal anti-Bcl-2 (6C8; a generous gift from Dr.
S. J. Korsmeyer at Washington University) followed by fluo-
rescein isothiocyanate-conjugated goat anti-hamster IgG and
examined using a Carl Zeiss Axiovert 100 equipped with
epifluorescence. For in situ labeling of nuclear DNA fragmen-
tation, terminal deoxynucleotidyltransferase-mediated nick
end-labeling (TUNEL) assay was carried out as previously
described (Gavrieli et al., 1992). Bright-field photomicrographs
were taken under a Carl Zeiss Axioplan2 microscope.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay
Approximately 2 3 104 cells of each stable cell line were
plated on a 25 mg/ml poly-D-lysine-coated 48-well plate (Corn-
ing), cultured in CCM for 2 days, and switched to serum-free
N2 medium with or without 1 mM staurosporine. If necessary,
a broad-spectrum caspase inhibitor, N-benzyloxycarbonyl-Val-
Ala-Asp-fluoromethyl ketone (Z-VAD; 200–400 mM) was ap-
plied with staurosporine. Following drug treatment for 24 h, the
rate of cell survival was measured using colorimetric MTT
reduction assay as described previously (Hansen et al., 1989;
Oh et al., 1997). Formazan grains formed by dehydrogenase
activity within the surviving cells were solubilized with 20%
SDS in 50% aqueous dimethylformamide overnight. The opti-
cal density of the dissolved grains was assessed at 540 nm
using an ELISA plate reader (Molecular Devices). Values from
each treatment were expressed as a percentage of survival over
the untreated matching control (100% survival).
JNK assay
MN9D cells from each transfectant were treated with 1 mM
staurosporine with or without 200 mM Z-VAD for the indicated
time periods, washed twice with cold PBS/EDTA buffer, and
lysed on ice for 15 min in 1% Nonidet P-40/20 mM HEPES
(pH 7.4) 100 mM NaCl/20 mM b-glycerophosphate/0.2 mM
sodium vanadate/1 mM EDTA/1 mM phenylmethylsulfonyl
fluoride/50 mg/ml aprotinin. After microcentrifugation, quanti-
fied amounts of the resulting supernatants were immunopre-
cipitated with mouse monoclonal anti-JNK1 antibody (Pharm-
ingen). The immunopellets were assessed for JNK1 activity as
described previously (Park et al., 1997). Glutathione S-trans-
ferase–c-Jun fusion protein was used as a substrate. The reac-
tion mixtures were subjected to electrophoresis on a 10%
SDS–polyacrylamide gel. Following autoradiography, the den-
J. Neurochem., Vol. 74, No. 4, 2000
1622 W.-S. CHOI ET AL.
sity of the phosphorylated proteins was quantitated by an image
analyzer (Fuji).
RESULTS
To establish the stable dopaminergic neuronal cell
line, MN9D overexpressing wild-type human Bcl-2 or
one of its structural mutant proteins, cells were trans-
fected with a cytomegalovirus major immediate early
enhancer/promoter-driven eukaryotic expression vector
containing a full-length human Bcl-2 or its structural
mutant cDNAs. Among randomly picked 12–24 G-418-
resistant clones from each transfectant, clones that ex-
pressed higher levels of equivalent mRNA were chosen
for further characterization by immunoblot analysis. As
shown in Fig. 1A, the endogenous level of Bcl-2 in
control MN9D/Neo cells was not readily detectable,
whereas all Bcl-2 transfectants demonstrated high levels
of wild-type Bcl-2 or its equivalent mutant proteins. As
demonstrated in Fig. 1B and C, a diffuse staining over
the whole cytosol and nuclei in MN9D/C22 cells was
distinctly different from that in the other Bcl-2 transfec-
tants.
When MN9D/Neo cells were first treated with 1 mM
staurosporine, dying cells exhibited TUNEL-positive nu-
clei typical of apoptosis compared with untreated
MN9D/Neo cells (Fig. 2A and B). This was consistent
with our previous studies in that staurosporine largely
induces apoptotic death in MN9D cells (Oh et al., 1997;
Kim et al., 1999). As determined by MTT reduction
assay, ;89.6% of MN9D/Neo cells were dead upon
exposure to staurosporine for 24 h (Fig. 2C). This was
largely attenuated in the presence of Z-VAD, suggesting
that caspase activation is involved. To evaluate the func-
tional role and requirement of structural motifs of Bcl-2
in sparing MN9D cells from staurosporine-induced cell
death, MN9D cells overexpressing Bcl-2 and its struc-
tural mutants were then treated with 1 mM staurosporine
for 24 h. Staurosporine-induced cell death was signifi-
cantly attenuated in MN9D/Bcl-2 cells (20.1% cell
death). The majority of MN9D/Bcl-2 cells were morpho-
logically intact, albeit round (not shown). As shown in
Fig. 2C, MN9D/BH1, MN9D/BH2, and MN9D/C22
cells were equally as protected as MN9D/Bcl-2 cells
upon staurosporine treatment. In contrast, staurosporine
killed both MN9D/BH3 and MN9D/BH4 cells. The rate
of cell death in these two transfectants was quite com-
parable with that in MN9D/Neo cells. Similar patterns
were obtained from at least two to three independently
derived clones from each transfectant (not shown).
It has been reported that the JNK pathway plays an
important role in the regulation of neuronal apoptosis
(Ham et al., 1995; Virdee et al., 1997). As shown in Fig.
3A, treatment of MN9D/Neo cells with 1 mM staurospor-
FIG. 2. Functional role of Bcl-2 and its structural mutant proteins
in staurosporine-induced MN9D cell death. TUNEL assay was
carried out in MN9D/Neo cells following treatment with a vehicle
(A) or 1 mM staurosporine (B) for 12 h. Cells from each transfec-
tant were plated at 2 3 104 on a poly-D-lysine-coated 48-well
plate, cultivated in CCM for 2 days, and switched to N2 medium
with or without 1 mM staurosporine for 20–24 h (C). If necessary,
200 mM Z-VAD (a broad-spectrum caspase inhibitor) was added.
Subsequently, viability was measured by the MTT reduction
assay. Values from each treatment were expressed as a percent
over the untreated control (100%). Each column represents the
mean 6 SEM from three independent experiments in triplicate.
FIG. 1. Characterization of MN9D cells overexpressing Bcl-2
and its structural mutant proteins. A: Immunoblot analysis of
Bcl-2 and its mutant proteins in MN9D/Neo (lane 1), MN9D/Bcl-2
(lane 2), MN9D/C22 (lane 7), MN9D/BH1 (lane 3), MN9D/BH2
(lane 4), MN9D/BH3 (lane 5), and MN9D/BH4 (lane 6) cells.
Rabbit polyclonal anti-Bcl-2 was used as the primary antibody
(1:3,000; Krajewski et al., 1993). Arrows indicate 30-kDa and
21.5-kDa molecular size markers, respectively. B and C: Immu-
nofluorescent localization of Bcl-2 was carried out in MN9D/
Bcl-2 (B) and MN9D/C22 (C) cells. For localization, a hamster
monoclonal anti-Bcl-2 antibody (1:100, 6C8) was followed by
fluorescein isothiocyanate-conjugated goat anti-hamster IgG.
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ine activated the JNK signaling pathway. Following stau-
rosporine treatment, activation of JNK started as early as
30 min and continuously increased thereafter up to six- to
sevenfold over the basal level of untreated MN9D/Neo
cells. This activation was not blocked in the presence of
200–400 mM Z-VAD, suggesting that caspase activation is
downstream of JNK activation. In MN9D/Bcl-2 cells, stau-
rosporine had a minimal effect on JNK activity (Fig. 3B).
To investigate whether there exists a correlation be-
tween the requirement of Bcl-2 structural motifs for
protection against staurosporine-induced cell death and
the blockage of JNK and caspase activation, each trans-
fectant was treated with 1 mM staurosporine for 2 h and
subjected to an assay for JNK activity. As shown in Fig.
4, activation of JNK activity was suppressed in MN9D/
BH1, MN9D/BH2, and MN9D/C22 cells following stau-
rosporine treatment. The rate of suppression in these
transfectants was quite similar to that in MN9D/Bcl-2
cells. In contrast, the rate of JNK activation upon stau-
rosporine treatment in MN9D/BH3 and MN9D/BH4
cells increased up to 3.7–6.2-fold over the untreated
matching control, which was comparable with that in
MN9D/Neo cells. When the cleavage pattern of PARP
by activated caspase was subsequently examined by im-
munoblot analysis (Kaufmann et al., 1993), specific
cleavage of PARP into the 85-kDa form was detected
following treatment with 1 mM staurosporine as early as
6 h in MN9D/Neo cells and continued up to 24 h (Fig. 5).
The formation of the 85-kDa band was seen in MN9D/
BH3 and MN9D/BH4 cells, whereas it was not detected
in MN9D/Bcl-2, MN9D/BH1, MN9D/BH2, or MN9D/
C22 cells up to 24 h (Fig. 5).
DISCUSSION
Previously, we have demonstrated that suppression of
the JNK signaling pathway in N18TG2 neuroglioma
cells may be critical for the protective action of Bcl-2
against various apoptotic stresses including staurospor-
ine (Park et al., 1997). The data presented here extend
our previous observations by demonstrating that overex-
pression of Bcl-2 in mesencephalon-derived MN9D do-
paminergic neuronal cells protects against staurosporine-
induced cell death by inhibiting JNK activation and its
downstream caspase activation as well. More impor-
tantly, we have first demonstrated that there exists a close
correlation between the structure of Bcl-2 and its func-
tion to inhibit JNK and caspase activity. In this cell death
paradigm, subcellular localization of Bcl-2 may not be
critical in that deletion of the carboxy-terminal mem-
brane-anchorage domain of Bcl-2 does not affect the
suppression rate of JNK and caspase activity or its anti-
apoptotic role. Similarly, we have also found that MN9D
cells overexpressing BH1 or BH2 point mutant protein
are equally protective. These data suggest that the known
hetero- and homodimerization domains among Bcl-2
family proteins may not be as important as previously
thought for the regulation of apoptosis in MN9D cells.
As previous findings indicate that BH3 and BH4 do-
FIG. 4. Regulation of JNK activity by Bcl-2 structural mutants.
Cells from MN9D/Neo, MN9D/Bcl-2, MN9D/C22, MN9D/BH1,
MN9D/BH2, MN9D/BH3, and MN9D/BH4 were plated at 1–2
3 106 on poly-D-lysine-coated P-100 Petri dishes, cultivated in
CCM for 2 days, switched to N2 medium containing 1 mM
staurosporine (STS) for 2 h, and then subjected to the JNK
assay. The intensity of the phosphorylated glutathione S-trans-
ferase–Jun was quantitated by phosphoimage analyzer. Values
were expressed as fold intensity over the untreated matching
control. Data represent the means 6 SD from three or four
independent experiments.
FIG. 5. Regulation of caspase activity by Bcl-2 structural mu-
tants as determined by immunoblot analysis for PARP. Cells
from MN9D/Neo, MN9D/Bcl-2, MN9D/C22, MN9D/BH1, MN9D/
BH2, MN9D/BH3, and MN9D/BH4 were plated at 1–2 3 106 on
poly-D-lysine-coated P-100 Petri dishes, cultivated in CCM for 2
days, and switched to N2 medium containing 1 mM staurospor-
ine for the indicated time periods. Cells were lysed and pro-
cessed for immunoblot analysis as described in Materials and
Methods. Specific bands of PARP and its cleaved form were
detected with a mouse monoclonal anti-PARP antibody
(1:5,000).
FIG. 3. JNK assay following staurosporine treatment in MN9D/
Neo (A) and MN9D/Bcl-2 (B) cells. Cells from MN9D/Neo and
MN9D/Bcl-2 were plated at 1–2 3 106 on poly-D-lysine-coated
P-100 Petri dishes, cultivated in CCM for 2 days, switched to N2
medium containing 1 mM staurosporine with or without 200 mM
Z-VAD (a broad-spectrum caspase inhibitor) for the indicated
time periods, and then subjected to the JNK assay as previously
described (Park et al., 1997).
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mains are necessary for Bcl-2 to interact with death-
regulatory proteins (H. G. Wang et al., 1996; K. Wang
et al., 1996; Huang et al., 1998), deletion of these do-
mains abrogates the death-inhibitory function of Bcl-2 in
staurosporine-induced MN9D cell death. Based on our
present data, at least one of the plausible mechanisms by
which BH3 and BH4 influence the fate of cell death
could be ascribed to its capacity to suppress JNK signal-
ing and its downstream caspase activition in MN9D
cells.
Earlier studies indicate that hetero- and homodimer-
ization through BH1 and BH2 are important for the
regulation of cell death by Bcl-2 family proteins (Oltvai
et al., 1993; Yin et al., 1994). Through BH1 and BH2
domains, Bcl-2 can, for example, heterodimerize with
the proapoptotic protein Bax, and the ratio of Bcl-2 to
Bax determines survival or death following various apo-
ptotic stimuli. Therefore, substitution of Gly145 in the
BH1 domain or Trp188 in the BH2 domain completely
abrogates the death-repressor activity of Bcl-2 in various
apoptotic cell death paradigms (Yin et al., 1994). Con-
trary to these early indications, others have recently
suggested that heterodimerization through the BH1 and
BH2 domain is not required for antiapoptotic function
(Cheng et al., 1996; Kelekar et al., 1997). In our labo-
ratory, we have observed that overexpression of the BH1
or BH2 point mutant Bcl-2 protein in PC12 cells does not
prevent staurosporine-induced apoptosis (I. I. Chang
et al., unpublished data). These observations from PC12
cells are quite contrary to our present finding that MN9D
cells overexpressing one of these point mutant proteins
can render protection against staurosporine-induced cell
death by effectively suppressing JNK and caspase activ-
ity. Interestingly, nigericin (potassium/proton iono-
phore)-induced caspase activation and subsequent cell
death are effectively blocked in both MN9D/BH1 and
MN9D/BH2 cells as well (J. H. Oh et al., unpublished
data). Although it is speculative at present, these contra-
dictory data may therefore raise the possibility that the
requirement of these dimerization domains of Bcl-2 may
be cell and/or stress type specific.
Most members of the Bcl-2 family possess a carboxy-
terminal transmembrane domain, but others including
Bid and Bad do not (Kroemer, 1997). It has been dem-
onstrated that the carboxy-terminal hydrophobic domain
of Bcl-2 is important in docking at the nuclear, outer
mitochondrial, and endoplasmic reticular membranes
(Nguyen et al., 1993, 1994; Oltvai et al., 1993). Anchor-
ing Bcl-2 to these strategic membrane locations and its
concentration at these sites in the cells seem to contribute
to its proposed antiapoptotic function (Nguyen et al.,
1994). Consequently, the ability of Bcl-2 to suppress
apoptosis has been demonstrated to abrogate or diminish
in constructs that lack carboxy-terminal transmembrane
domain or in constructs in which the single predicted
transmembrane domain is replaced by the corresponding
domain of a plasma membrane protein (Alnemri et al.,
1992; Hockenbery et al., 1993; Tanaka et al., 1993).
Similarly, fusion of a heterologous transmembrane do-
main to Bcl-2 protein that lacks the carboxy-terminal
domain restores antiapoptotic function (Tanaka et al.,
1993). It has been suggested that cytochrome c release
from the mitochondria to cytosol eventually activates
effector caspases, leading to apoptotic cell death in re-
sponse to stresses including staurosporine (Kluck et al.,
1997; Yang et al., 1997). Based on these findings, it has
been proposed that anchored Bcl-2 at the outer mem-
brane of mitochondria may act to inhibit translocation of
cytochrome c and subsequent caspase activation in the
apoptotic process. However, a deletion of the carboxy
terminal does not abrogate the inhibitory effect of Bcl-2
on staurosporine-induced JNK and caspase activation in
MN9D cells. Our present data are consistent with another
finding demonstrating that a carboxy-terminal truncation
mutant of Bcl-2 shows full activity in blocking apoptosis
of nerve growth factor-deprived sympathetic neurons
and tumor necrosis factor-a-treated fibroblasts (Borner
et al., 1994). Therefore, it may be that the requirement of
the membrane anchorage domain of Bcl-2 also depends
on cell type and/or stress type.
Although the mechanism of apoptosis is proposed to
be remarkably conserved, the expected greater complex-
ity and diversity in mammals seem to exist. For example,
it appears that the structure–function requirement of the
Bcl-2 family may be more complicated than thought
before. Further studies delineating the cell type and/or
stress type specificity will expand our present under-
standing of how cell death-regulatory proteins such as
the Bcl-2 family and other structurally unrelated proteins
interact to modulate the dynamic equilibrium of cell life
and death.
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